Welcome to our dedicated page for Baxter Intl news (Ticker: BAX), a resource for investors and traders seeking the latest updates and insights on Baxter Intl stock.
Baxter International Inc (NYSE: BAX) is a global healthcare leader specializing in life-saving renal care, advanced medical devices, and hospital solutions. This page provides investors and healthcare professionals with timely updates on the company’s operational developments, regulatory milestones, and strategic initiatives.
Access authoritative information about Baxter’s latest financial results, product innovations, and partnerships. Our curated news collection simplifies tracking of critical updates across key areas including dialysis technologies, infusion systems, and biosurgery products.
Discover official announcements regarding:
• Quarterly earnings and financial guidance
• New product approvals and clinical trials
• Strategic acquisitions in medical technology
• Regulatory compliance updates
• Leadership changes and corporate governance
Bookmark this page for streamlined access to Baxter’s verified news developments. Check regularly for updates that may impact market positioning and healthcare sector trends.
Baxter International Inc. (NYSE:BAX) presented critical care study findings at the 34th Annual European Society of Intensive Care Medicine (ESICM) LIVES virtual congress from Oct. 3-6, 2021. The data emphasized personalized healthcare approaches for patients with acute kidney injury (AKI) or sepsis. A study revealed the prevalence of persistent severe AKI (PS-AKI) among hospitalized adults, significantly increasing mortality risks. Additionally, findings from the FRESH clinical trial indicated that dynamic fluid management may improve kidney function in septic patients. Baxter also organized symposia on digital transformation and fluid management.
Baxter International Inc. (NYSE:BAX) will host a conference call on October 28, 2021, at 7:30 a.m. Central Time to discuss its third-quarter 2021 financial results. Participants can pre-register using the provided link or access the call via webcast on Baxter's website. With over 85 years in the industry, Baxter continues to offer critical care, nutrition, and surgical products globally. The meeting underscores Baxter's commitment to transparency and investor communication as it prepares to share key financial insights.
Baxter International Inc. (NYSE:BAX) has received FDA approval for its premix Norepinephrine Bitartrate in 5% Dextrose Injection, the first ready-to-use formulation of norepinephrine, which is crucial for treating severe hypotension in adults. Available in 4 mg/250 mL and 8 mg/250 mL concentrations, this formulation enhances patient safety by reducing compounding errors and offers flexible storage options, including room temperature. The product features a shelf life of up to 21 months in refrigeration and up to 90 days at room temperature, utilizing Baxter's proprietary VIAFLO container technology.
Baxter International has announced its acquisition of Hillrom for $156.00 per share, totaling $10.5 billion in cash. This strategic move aims to enhance access to care and accelerate digital health solutions globally. The acquisition is expected to generate approximately $250 million in annual pre-tax cost synergies by year three, with a positive impact on Baxter's adjusted earnings per share (EPS) projected to exceed 20% by year three. Both companies' boards have unanimously approved the deal, which is set to close by early 2022.
The Baxter International Foundation has partnered with UNICEF USA to enhance access to safe water in La Guajira, Colombia, through a $1.5 million grant. This three-year initiative aims to benefit thousands of children and families by improving water, sanitation, and hygiene (WASH) services via rehabilitation, education, and collaboration. With alarming statistics indicating a significant lack of access to clean water, this project will include rehabilitating water systems and distributing hygiene kits. Baxter's long-standing commitment to community health aligns with this initiative's goal of supporting sustainable access to clean water.
Baxter International Inc. (NYSE:BAX) is advancing its digital transformation by focusing on three areas: enhancing digital health solutions, improving customer experiences, and modernizing technology capabilities. Collaborating with Amazon Web Services, Baxter is moving its data centers to the cloud, which has led to increased speed, geographical expansion, and cost savings. This transformation supports its digital health solutions, including the Sharesource remote patient management platform for home dialysis, and enhances its supply chain resilience amid global challenges. The company is also investing in employee digital training.
Baxter International (NYSE:BAX) will present at the UBS Genomics 2.0 and MedTech Innovations Summit on August 12, 2021, at 10:00 a.m. PT. Jay Saccaro, Baxter’s CFO, is scheduled to speak. The live webcast will be accessible at www.baxter.com and available for replay until August 11, 2022. Baxter has been a leader in medical products for over 85 years, providing critical care, nutrition, renal, and surgical solutions across more than 100 countries, advancing healthcare innovations for patients and caregivers.
CryoLife, Inc. (NYSE: CRY) announced the sale of its PerClot product line to Baxter International (NYSE: BAX) for up to $60.8 million. CryoLife will receive up to $45.8 million, while Starch Medical, Inc. will receive up to $15 million. The transaction includes worldwide marketing rights and related assets. CryoLife will also provide transition services and remain responsible for FDA approval efforts. Proceeds will be used for general corporate purposes, contingent obligations, and potential debt repayment.
Baxter International has completed the acquisition of assets related to PerClot Polysaccharide Hemostatic System from CryoLife for up to $60.8 million, including $25 million upfront. This strategic move aims to enhance Baxter’s offerings in the operating room, particularly in managing intraoperative bleeding. PerClot is not yet cleared for sale in the U.S. but is sold in over 35 countries. The acquisition aligns with Baxter's commitment to optimize patient care and expand its hemostatic product line, complementing its recent purchase of Seprafilm.
Baxter International Inc. (NYSE:BAX) reported a strong second-quarter 2021, with worldwide sales reaching approximately $3.1 billion, reflecting a 14% year-over-year increase. The U.S. sales grew 6% to $1.2 billion, while international sales surged 19% to $1.9 billion. Key drivers included growth in BioPharma Solutions and Advanced Surgery. Net income attributable to Baxter reached $298 million, or $0.59 per diluted share, marking a 23% increase. Adjusted net income was $409 million, exceeding guidance. Baxter also announced strategic product launches and plans for its Investor Conference in September.
